- Medicine Name: Prevymis
- Generic Name: Letermovir
- Dosage Form & Strength: Tablet: 240 mg; 480 mg and Injection: 240 mg/12 mL (20 mg/mL) or 480 mg/24 mL (20 mg/mL) in a single-dose vial
- Manufactured By: Merck
Prevymis is a CMV DNA terminase complex inhibitor used for prophylaxis of cytomegalovirus (CMV) infection and disease in adult CMV-seropositive recipients [R+] of an allogeneic hematopoietic stem cell transplant (HSCT).
Recommended Dosage: Prevymis Tablet is administered with or without food. Swallow tablets whole. Prevymis Injection is administered by intravenous infusion via a peripheral catheter or central venous line at a constant rate over 1 hour. Do not administer it as an intravenous bolus injection.
The recommended dosage is 480 mg administered orally or intravenously once daily. Initiate therapy between Day 0 and 28’th post-transplantation (prior to or after engraftment), and continue through Day 100’th post-transplantation.
Use prevymis injection, which contains hydroxypropyl betadex, only in those who are unable to take oral therapy. Patients should be switched to oral Prevymis as promptly as they are able to take oral medications. Prevymis injection and tablet may be used interchangeably at the discretion of the health specialist, and no dosage adjustment is required when switching formulations.
If Prevymis is co-administered with drug cyclosporine, the dosage of Prevymis should be reduced to 240 mg once daily.
- If medicine cyclosporine is initiated after initiating Prevymis, the next dose of Prevymis should be reduced to 240 mg once daily.
- If medicine cyclosporine is discontinued after initiating Prevymis, the next dose of Prevymis should be reduced to 480 mg once daily.
- If dosing of medicine cyclosporine is temporarily interrupted because of high cyclosporine levels, no dose adjustment is required.
All Trademarks and Brands that appear on the website belong to their respective owners and indianpharmanetwork does not lay any claim on them we only provide Information.